Skip to main content
Top
Published in: Familial Cancer 3/2013

01-09-2013 | Forward

Birt–Hogg–Dubé syndrome

Authors: Maria F. Czyzyk-Krzeska, Francis X. McCormack

Published in: Familial Cancer | Issue 3/2013

Login to get access

Excerpt

Birt–Hogg–Dubé (BHD) syndrome is a rare autosomal dominant disorder associated with renal cysts and cancer, lung cysts, pneumothorax and skin fibrofolliculomas. The disease is caused by germline mutations in the FLCN gene located on chromosome 17p11.2 that result in loss of function of the tumor suppressor, folliculin. While the genetic basis of BHD has been well established, the biochemical and signaling functions of FLCN remain incompletely understood. To address this knowledge deficit, the Myrovlytis Trust and BHD Foundation have conducted annual meetings over the past 5 years to promote scientific interaction between scientists and clinicians interested in BHD. The Fourth Annual BHD meeting took place in March 2012 in Cincinnati, Ohio. This special issue of Familial Cancer summarizes the new data presented and the status of knowledge discussed at the meeting, from both the basic and clinical perspective. The authors provide an overview of the currently understood functions of FLCN, as well as recommendations for detection and treatment of BHD. …
Literature
1.
go back to reference Schmidt LS, Nickerson ML, Warren MB et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 76:1023–1033PubMedCrossRef Schmidt LS, Nickerson ML, Warren MB et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 76:1023–1033PubMedCrossRef
2.
go back to reference Nickerson ML, Warren MB, Toro JR et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2:157–164PubMedCrossRef Nickerson ML, Warren MB, Toro JR et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2:157–164PubMedCrossRef
3.
go back to reference Vocke CD, Yang Y, Pavlovich CP et al (2005) High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 97:931–9315PubMedCrossRef Vocke CD, Yang Y, Pavlovich CP et al (2005) High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 97:931–9315PubMedCrossRef
5.
go back to reference Nahorski MS, Seabra L, Straatman-Iwanowska A et al (2012) Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. Hum Mol Genet 21:5268–5279PubMedCrossRef Nahorski MS, Seabra L, Straatman-Iwanowska A et al (2012) Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. Hum Mol Genet 21:5268–5279PubMedCrossRef
6.
go back to reference Medvetz DA, Khabibullin D, Hariharan V et al (2012) Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell–cell adhesion. PLoS One 7:e47842PubMedCrossRef Medvetz DA, Khabibullin D, Hariharan V et al (2012) Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell–cell adhesion. PLoS One 7:e47842PubMedCrossRef
7.
Metadata
Title
Birt–Hogg–Dubé syndrome
Authors
Maria F. Czyzyk-Krzeska
Francis X. McCormack
Publication date
01-09-2013
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2013
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9679-y

Other articles of this Issue 3/2013

Familial Cancer 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine